Biotechnology

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Annual Earnings on April 29 (EST), actual revenue USD 4.659M, actual EPS USD -4.5999

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Q4 earnings on April 29, 2026 (EST), with actual revenue of USD 1.404M and EPS of USD -1.3486

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 9 Months earnings on April 29, 2026 (EST), actual revenue USD 2.558 M, actual EPS USD 0.4129

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 Q3 earnings on April 29 (EST), actual revenue USD 2.27 M, actual EPS USD 1.962

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 9 Months earnings on April 29 (EST), actual revenue USD 3.255M, actual EPS USD -3.2486

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2023 earnings on April 29 (EST), actual revenue USD 3.33 M (forecast USD 4.6 M), actual EPS USD -2.4

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Q3 earnings on April 29 EST, actual revenue USD 1.404 M, actual EPS USD -1.3486

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 Q4 earnings on April 29 EST, actual revenue USD 2.27 M, actual EPS USD 1.962

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 earnings on April 29 (EST), actual revenue USD 4.828 M (forecast USD 15.25 M), actual EPS USD 2.1

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2023 Q4 earnings on April 29 (EST), actual revenue USD 90K, actual EPS USD -0.7521

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Q1 earnings on August 28 (EST), actual revenue USD 925.5K, actual EPS USD -0.9499

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Q2 earnings on August 28, 2025 (EST) with actual revenue of USD 925.5K and EPS of USD -0.9499

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 Semi-Annual earnings on August 28, 2025 (EST), actual revenue USD 288 K (forecast USD 2 M), actual EPS USD -1.5491

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2025 Semi-Annual Earnings on August 28 (EST), actual revenue USD 1.851 M (forecast USD 27.2 M), actual EPS USD -1.8999

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 Q1 earnings on August 28 (EST), actual revenue USD 144K, actual EPS USD -0.7745

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2024 Q2 earnings on August 28, 2025 (EST), actual revenue USD 144K, actual EPS USD -0.7745

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2023 Q3 earnings on April 30, 2025 (EST), with actual revenue of USD 90K and EPS of USD -0.7521

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2022 earnings on April 30 (EST), actual revenue USD 15.62 M (forecast USD 7.4 M), actual EPS USD -1.7999

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS released FY2022 Q4 earnings on April 30, 2025 (EST), with actual revenue of USD 4.294 M and EPS of USD -0.3989

DevvStream

Hub Cyber Security

Sunlands Tech

PRF Tech

Mynd.ai

Replimune

Tortoise Energy Infrastructure Corporation

Olenox Industries

Astrotech

GraniteShares 2x Long DELL Daily ETF

PRTC

PRTCY

PureTech Health (LON:PRTC) shares fell 9.2% to GBX 126, with 1,066,844 shares traded, a 15% decline from average volume. The company has a market cap of £306.71 million, a PE ratio of -2.74, and a debt-to-equity ratio of 6.33. Analysts currently rate the stock as a Buy, but it is not among the top recommendations. PureTech focuses on developing treatments for nervous, gastrointestinal, and immune system disorders.

Market Beat

PureTech Health

PureTech Health (LON:PRTC)  Shares Down 9.2%   - Time to Sell?

PureTech Health's Q4 earnings call highlighted a balance between clinical progress and financial pressures. The company reported a cash position of $277.1M at year-end 2025, down from $366.8M in 2024, and a net loss of $110.1M in 2025. Key programs like Gallop's LYT-200 and Celea's Deupirfenidone showed promise, but future trials will depend on external funding. Management outlined a strategic overhaul to improve returns, including a potential Nasdaq delisting and a focus on fewer development candidates. Revenues remained modest at $4.7M, with significant reliance on milestones and royalties.

Tip Ranks

Seaport ENT

Nasdaq

PureTech Health Balances Clinical Wins With Cash Demands

PureTech Health (NASDAQ:PRTC) reported quarterly earnings of ($1.35) EPS, exceeding estimates of ($1.94) by $0.59. Revenue was $1.40 million, below the expected $1.90 million. The company plans to delist from Nasdaq to cut costs and aims to launch entities earlier for capital leverage. PureTech has $248.1 million in cash, ensuring operational runway through 2028. Despite a 4.9% drop in stock price to $17.25, analysts maintain a "sell" rating, with institutional investors increasing their holdings. PureTech focuses on developing first-in-class medicines across various therapeutic areas.

MarketWise

PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS

PureTech reports FY results, will delist ADS from Nasdaq

businessinsider

PureTech reports FY results, will delist ADS from Nasdaq

PureTech Health plc announced its annual results for the year ended December 31, 2025, highlighting a refined strategy and a cash balance of $277.1 million. The company is advancing its portfolio, including Celea Therapeutics’ Phase 3-ready deupirfenidone and Gallop Oncology’s LYT-200. CEO Robert Lyne emphasized the importance of capital deployment and external investment for development. PureTech plans to delist from Nasdaq and focus on the London Stock Exchange to streamline operations. A conference call is scheduled for April 29, 2026, to discuss these results.

StockTitan

PureTech Announces Annual Results for Year Ended December 31, 2025 | PRTC Stock News

PureTech Health plc announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq, focusing trading on the London Stock Exchange (LSE). This decision aims to enhance operational efficiency and align with the company's primary investor base in the UK. The delisting is expected to be effective around May 20, 2026, following a Form 25 filing with the SEC. PureTech's CEO emphasized that this move will streamline governance and preserve capital, allowing the company to concentrate on advancing its biotherapeutics portfolio.

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange | PRTC Stock News

Seaport Therapeutics (SPTX) has filed for an IPO to raise up to $212M by offering 11.8M shares priced between $16 and $18 each. The company, focused on developing oral therapies for neuropsychiatric diseases, aims for a market value of $912M at the top share price. Goldman Sachs, JP Morgan, and Leerink Partners are leading the offering. Seaport reported a net loss of $74.9M last year and is backed by PureTech Health, which owns nearly 50% of the company.

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Goldman Sachs

GS Hldg R

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

ITCI

BNTC

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | BNTC Stock News

Intra-Cellular Therap

Benitec Biopharma

iShares Global Healthcare

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | BNTC Stock News

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) experienced a significant increase in short interest, rising 30.8% in March to 14,823 shares. This represents 0.1% of the company's shares sold short, with a days-to-cover ratio of 4.6 days based on an average daily volume of 3,250 shares. Institutional investor Pentwater Capital Management LP increased its stake by 50% in the third quarter. Analysts maintain a "Sell" rating on the stock, which is currently trading at $18.23, up 2.0%.

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March

ACHC

AHCO

Ada Health has been granted a patent by the European Patent Office for its hybrid AI architecture, which combines large language models (LLMs) with clinical precision and regulatory compliance. This innovative system enhances accuracy and user-friendliness in healthcare by integrating a probabilistic graphical model with an LLM. The patented architecture ensures clinical safety by dynamically prompting users with relevant medical questions and providing a second opinion through Ada's expert-curated knowledge base. This development aims to improve the deployment of AI in healthcare, addressing safety concerns associated with general-purpose LLMs.

prnewswire

Acadia Healthcare

AdaptHealth

08:24 ETAda Health Patents the Clinical Layer That Makes LLMs Safe for Healthcare

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS(PRTCY.US)

PureTech Health (LON:PRTC) Shares Down 9.2% - Time to Sell?

PureTech Health Balances Clinical Wins With Cash Demands

PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS

PureTech reports FY results, will delist ADS from Nasdaq

PureTech Announces Annual Results for Year Ended December 31, 2025 | PRTC Stock News

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange | PRTC Stock News

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | BNTC Stock News

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March

08:24 ETAda Health Patents the Clinical Layer That Makes LLMs Safe for Healthcare